THREAD signs on with Allucent to launch DCTs for smaller biotechs

Decentralized clinical trial tech company THREAD Research signed on with Allucent to launch a new services platform directed at small and emerging biotech companies navigating their way through remote trials

Dubbed Allucent Patient Direct Trials, the platform focuses on meeting the needs of smaller biotechs that typically don’t have in-house resources to facilitate decentralized trials. With THREAD on board, Allucent’s consultants will be able to guide sponsors to identify digital strategies for remote patient engagement and data collection, the company said in a May 23 press release.

Financial terms of the collaboration weren’t disclosed.

Adoption of DCTs following the global COVID-19 crisis has morphed into not just overcoming disruptions but also a way to speed recruiting, retain trial participants and increase the diversity of participants who have been underrepresented in past trials.

THREAD has been on a growth spurt of late. In January, the company acquired fellow DCT tech company InVibe for an undisclosed sum. That acquisition followed THREAD’s purchase of Modus Outcomes, a research consultant service that supports the design and selection of electronic clinical outcome assessments, participant-focused trial design and scientific delivery of DCTs.